willdate

11 POSTS 0 COMMENTS

CX 2021 poll sees thrombolysis trump endovascular treatment in basilar artery...

A series of debates tested expert response to current acute stroke controversies during the final day of the Charing Cross (CX) 2021 Digital Edition...

Evolution of radial access in the neurovascular space

This advertorial is sponsored by Medtronic The field of neurointervention has seen a dramatic increase in the adoption of radial artery access over the past...

Terumo reaches agreement to acquire predictive analytics specialist Health Outcomes Sciences

Terumo Corporation has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, a specialist in predictive analytics and clinical decision support...

Coil pliability matters: Novel metrics for assessment of in vitro coil...

This advertorial is sponsored by Medtronic Neurovascular The deployment of an embolisation coil is “much more art than science” according to Daniel Sahlein (Goodman Campbell...

Neuro News Issue 39 – US Edition

Highlights: Comprehensive coverage from the Society of NeuroInterventional Surgery (SNIS) 17th Annual meeting (4–7 August) including two new studies to describe outcome-related racial disparities...

NeuroNews Issue 39

Highlights: Comprehensive coverage from the Society of NeuroInterventional Surgery (SNIS) 17th Annual meeting (4–7 August) including two new studies to describe outcome-related racial disparities...

Stroke treatment in the fast lane

The last five years have seen endovascular therapy for patients with acute ischaemic stroke proven undeniably effective, changing the face of stroke treatment forever. While...

Stryker develops Emergency Relief Bed in response to COVID-19 pandemic

Stryker has announced the development of a limited-release emergency response bed to quickly aid healthcare providers with efficient care during the COVID-19 pandemic. The Emergency...

AHA commits US$2.5 million for fast-tracked COVID-19 heart and brain research

The American Heart Association (AHA) has committed US$2.5 million to research efforts to better understand the novel coronavirus, COVID-19, and its interaction with the...

Neuroprotective drug elicits beneficial effects in the 40% of patients who...

The final results of the ESCAPE-NA1 trial have been presented and published contemporaneously in The Lancet. The study investigated the safety and efficacy of...

GTX Medical and NeuroRecovery Technologies announce merger

GTX Medical (formerly G-Therapeutics) and NeuroRecovery Technologies (NRT) have announced a merger, creating a global company for the development of neuromodulation therapies to aid...